Alasdair Coles

Research interests

Publications

• Neurological Implications of COVID-19 Infections

  Neurocritical Care · 2020 · https://doi.org/10.1007/s12028-020-00978-4

• Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study

  The Lancet Neurology · 2020 · https://doi.org/10.1016/s1474-4422(20)30067-3

• Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis

  JAMA · 2019 · https://doi.org/10.1001/jama.2018.20588

• Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study

  The Lancet Neurology · 2017 · https://doi.org/10.1016/s1474-4422(17)30007-8

• Alemtuzumab CARE-MS II 5-year follow-up

  Neurology · 2017 · https://doi.org/10.1212/wnl.0000000000004354

• Alemtuzumab CARE-MS I 5-year follow-up

  Neurology · 2017 · https://doi.org/10.1212/wnl.0000000000004313

• Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

  The Lancet · 2012 · https://doi.org/10.1016/s0140-6736(12)61769-3

• Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

  The Lancet · 2012 · https://doi.org/10.1016/s0140-6736(12)61768-1

• Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 Clinical Trial

  Neurology · 2012 · https://doi.org/10.1212/wnl.0b013e31824e8ee7

• Mutations in the selenocysteine insertion sequence–binding protein 2 gene lead to a multisystem selenoprotein deficiency disorder in humans

  Journal of Clinical Investigation · 2010 · https://doi.org/10.1172/jci43653

• Multiple sclerosis

  The Lancet · 2008 · https://doi.org/10.1016/s0140-6736(08)61620-7

Current projects

No projects listed.